Skip to main content

Table 1 Association between PEG10 expression and clinical characteristics in 147 hepatocellular carcinoma patients

From: miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma

  PEG10 (+) PEG10 (−) P value
N = 83 N = 64
Age (mean) 62.95 62.31 0.662
Gender (M) 58 (69.9 %) 46 (71.9 %) 0.792
Tumor size (cm)    0.231
 <2 17 (20.5 %) 7 (10.9 %)  
 2–5 39 (47.0 %) 30 (46.9 %)  
 >5 27 (32.5 %) 27 (42.2 %)  
Vascular invasion 32 (38.6 %) 25 (39.1 %) 0.950
Liver cirrhosis 55 (66.3 %) 42 (65.6 %) 0.935
AJCC T-stage    0.144
 I 49 (59.0 %) 36 (56.3 %)  
 II 17 (20.5 %) 11 (17.2 %)  
 III 16 (19.3 %) 11 (17.2 %)  
 IV 1 (1.2 %) 6 (9.4 %)  
BCLC stage    0.159
 0 9 (10.8 %) 2 (3.1 %)  
 A 44 (53.0 %) 34 (53.1 %)  
 B 26 (31.3 %) 27 (42.2 %)  
 C 4 (4.8 %) 1 (1.6 %)  
Okuda stage    0.050
 I 79 (95.2 %) 55 (85.9 %)  
 II 4 (4.8 %) 9 (14.1 %)  
Etiology    0.173
 Non-viral 11(13.3 %) 15 (23.8 %)  
 HBV 40 (48.2 %) 31 (48.4 %)  
 HCV 28 (33.7 %) 13 (20.3 %)  
 Both 4 (4.8 %) 5 (7.8 %)  
Histological grade    0.001
 Well 6 (7.2 %) 19 (29.7 %)  
 Moderate 61 (73.5 %) 32 (50 %)  
 Poor 16 (19.3 %) 13 (20.3 %)  
Recurrence (>2 year) 12 (14.5 %) 4 (6.3 %) 0.113
AFP (>500 ng/ml) 17 (30.1 %) 5 (15.6 %) 0.055
  1. AJCC American Joint Committee on Cancer, BCLC Barcelona Clinic Liver Cancer, HBV hepatitis B virus, HCV hepatitis C virus, AFP α-fetoprotein